Flumazenil
Competitive antagonist and inverse agonist of the benzodiazepine receptor.
| Property | Action |
|---|---|
| Class | Imidazo-benzodiazepine |
| Uses | Reversal of BZD |
| Route of Administration | IV |
| Dosing | 0.1mg boluses up to 2mg |
| Onset | Within 2 minutes |
| Distribution | Moderate lipid solubility, 50% protein bound. t1/2β < 1 hour - may require infusion. |
| Metabolism | Hepatic to inactive metabolites |
| Elimination | Renal of metabolites |
| CNS | May precipitate seizures or BDZ withdrawal due to inverse agonist effect |
| GIT | N/V |
References
- Petkov V. Essential Pharmacology For The ANZCA Primary Examination. Vesselin Petkov. 2012.